1 week Ago By ABMN Staff
Humana Inc. ( NYSE:HUM – Get Free Report ) insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st.
The shares were sold at an average price of $256.26, for a total value of $948,930.78.
Following the completion of the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This represents a 31.
16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link . Humana Stock Up 3.
9 % HUM opened at $262.47 on Friday. The business’s fifty day simple moving average is $272.
56 and its 200 day simple moving average is $314.60. Humana Inc.
has a 52 week low of $213.31 and a 52 week high of $471.37.
The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.
67. The stock has a market cap of $31.60 billion, a PE ratio of 23.
25, a P/E/G ratio of 2.12 and a beta of 0.53.
Humana ( NYSE:HUM – Get Free Report ) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating the consensus estimate of $3.
48 by $0.68. The firm had revenue of $29.
30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.
20% and a net margin of 1.18%. As a group, research analysts expect that Humana Inc.
will post 16.14 earnings per share for the current fiscal year. Humana Announces Dividend Analyst Upgrades and Downgrades A number of research firms have recently weighed in on HUM.
TD Cowen increased their target price on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th.
Sanford C. Bernstein raised Humana from a “market perform” rating to an “outperform” rating and set a $308.00 target price for the company in a research report on Tuesday, October 8th.
Barclays upped their price target on Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st.
Oppenheimer decreased their price objective on Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a report on Thursday, October 3rd.
Finally, Wells Fargo & Company dropped their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th.
Twenty equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $300.
50. Get Our Latest Stock Report on Humana Hedge Funds Weigh In On Humana A number of large investors have recently added to or reduced their stakes in the business. Moors & Cabot Inc.
boosted its position in Humana by 2.5% during the third quarter. Moors & Cabot Inc.
now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after buying an additional 40 shares during the period. OLD National Bancorp IN lifted its stake in shares of Humana by 1.8% in the 3rd quarter.
OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock valued at $828,000 after acquiring an additional 45 shares during the last quarter. Your Advocates Ltd. LLP lifted its stake in shares of Humana by 81.
8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the last quarter.
Brooklyn Investment Group boosted its holdings in Humana by 6.7% during the 3rd quarter. Brooklyn Investment Group now owns 736 shares of the insurance provider’s stock valued at $233,000 after acquiring an additional 46 shares during the period.
Finally, Deseret Mutual Benefit Administrators lifted its position in Humana by 18.4% in the second quarter. Deseret Mutual Benefit Administrators now owns 303 shares of the insurance provider’s stock valued at $113,000 after purchasing an additional 47 shares during the last quarter.
Hedge funds and other institutional investors own 92.38% of the company’s stock. About Humana ( Get Free Report ) Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States.
It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Stories Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter ..
